The diagnosis and management of metastatic melanoma require robust radiological protocols. Therefore, the European Society of Oncologic Imaging recently published updated melanoma imaging guidelines to standardize patient staging and treatment assessment. Specifically, these recommendations help clinicians navigate the highly atypical metastatic pathways that this disease frequently exhibits.
Implementing Melanoma Imaging Guidelines for Staging
First, standard imaging protocols must utilize comprehensive body CT or PET/CT along with dedicated brain MRI. However, radiologists must remain highly vigilant during baseline assessments. Indeed, melanoma often presents with atypical metastatic sites, including gastrointestinal, splenic, or endobronchial lesions. Consequently, a superficial analysis might easily miss these unusual lesions. Therefore, imaging professionals must scrutinize every organ with immense precision. Ultimately, precise staging directly dictates the therapeutic pathway for the patient.
Navigating Complex Immunotherapy Response Patterns
Evaluating response to immunotherapy introduces significant challenges in clinical practice. For instance, checkpoint inhibitors frequently trigger atypical response patterns like pseudoprogression and dissociated response. Consequently, a temporary increase in tumor size can mimic disease progression on standard imaging. Therefore, radiologists should utilize specialized immune-adapted response criteria to avoid misinterpretation. Specifically, criteria like iRECIST provide a standardized framework to confirm true progressive disease. Ultimately, implementing these criteria prevents the premature cessation of life-saving immunotherapies. In addition, adopting these structured reporting systems enhances communication with the treating oncologists.
Recognizing Treatment Complications and Mimics
Furthermore, the widespread adoption of immunotherapy exposes patients to unique side effects. For example, clinicians must detect immune-related adverse events early to ensure patient safety. Additionally, some benign inflammatory reactions can easily mimic active tumor progression. In particular, sarcoid-like reactions often cause new mediastinal and hilar lymphadenopathy. Thus, radiologists must identify these non-malignant changes to avoid overcalling disease progression. Similarly, the growing use of intratumoral immunotherapy can induce localized inflammatory changes at the injection sites. Consequently, clinicians can utilize a dedicated modification known as itRECIST to evaluate these local changes. Consequently, understanding these mimics ensures highly accurate clinical reporting.
Frequently Asked Questions
Q1: Why are specialized imaging criteria necessary for evaluating melanoma response to immunotherapy?
Traditional RECIST 1.1 criteria rely strictly on lesion size, which can mistake immune-mediated pseudoprogression for disease advancement. Therefore, iRECIST requires a confirmatory scan to rule out temporary cell infiltration before declaring treatment failure.
Q2: What is itRECIST, and when should clinicians apply it?
itRECIST is a dedicated adaptation of the response criteria designed specifically for intratumoral immunotherapy. Specifically, it helps radiologists distinguish local inflammatory changes at injection sites from true progressive disease.
Q3: How do sarcoid-like reactions complicate melanoma response assessments?
Sarcoid-like reactions represent an immune-related adverse event that can manifest as newly developed mediastinal and hilar lymphadenopathy. Because these benign nodes can easily mimic disease progression, radiologists must identify them carefully to avoid overcalling treatment failure.
References
- Kunz WG et al. ESR Essentials: imaging of melanoma-practice recommendations by the European Society of Oncologic Imaging. Eur Radiol. 2026 May 29. doi: 10.1007/s00330-026-12639-9. PMID: 42213112.
- Seymour L et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. PMID: 28254116.
- Goldmacher GV et al. Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST. J Clin Oncol. 2020 Aug 10;38(23):2619-2626. doi: 10.1200/JCO.19.02725. PMID: 32412866.